EGFR and non-small cell lung carcinoma: The KEYNOTE-789 study is a randomized, double-blind, phase 3 trial evaluating the efficacy of adding pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic non-squamous NSCLC (122).